PRKAA1 and non-small cell lung carcinoma: Previous studies have shown that higher concentrations (over 10–100 μM) of traditional AMPK activators, such as AICAR and metformin, can induce anticancer effects in non-small cell lung carcinoma cells [50,51,52,53].